Publications by authors named "R M Pascuzzi"
Article Synopsis
- The study aimed to assess the safety and effectiveness of caprylate/chromatography-purified intravenous immunoglobulin (IGIV-C) in patients with generalized myasthenia gravis (MG) compared to a placebo.
- A total of 62 patients participated in a randomized trial, where IGIV-C showed a numerical improvement in certain outcomes like activities of daily living, although most primary and secondary outcomes did not reach statistical significance.
- While IGIV-C was generally well-tolerated, the small size of the study suggests the need for further research to better understand its potential as a maintenance therapy for MG.
Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study.
Ther Adv Neurol Disord
September 2024
Article Synopsis
- The study investigates the effectiveness and safety of rozanolixizumab in treating patients with muscle-specific tyrosine kinase (MuSK) autoantibody-positive generalized myasthenia gravis (gMG), which is a severe form of the condition.
- Conducted as a randomized, double-blind, placebo-controlled phase III trial, it involved participants aged 18 and older who were randomly assigned to receive either rozanolixizumab (at two different dosages) or a placebo over 6 weeks.
- Results showed significant improvements in the Myasthenia Gravis Activities of Daily Living (MG-ADL) scores for both doses of rozanolixizumab compared to placebo, with manageable side effects reported;
Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome: New Developments in Diagnosis and Treatment.
Neuropsychiatr Dis Treat
December 2022
"Myasthenia Gravis is, like it or not, the neurologist's disease!" (Thomas Richards Johns II, MD 1982). The most common disorders in clinical practice involving defective neuromuscular transmission are myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS). The hallmark of weakness related to malfunction of the neuromuscular junction (NMJ) is variability in severity of symptoms from minute to minute and hour to hour.
View Article and Find Full Text PDFBackground And Objectives: Myasthenia gravis (MG) is an autoimmune disease characterized by dysfunction at the neuromuscular junction. Treatment frequently includes corticosteroids (CSs) and IV immunoglobulin (IVIG). This study was conducted to determine whether immune globulin (human), 10% caprylate/chromatography purified (IGIV-C) could facilitate CS dose reduction in CS-dependent patients with MG.
View Article and Find Full Text PDFMyasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) are the most common disorders of neuromuscular transmission in clinical practice. Disorders of the neuromuscular junction (NMJ) are characterized by fluctuating and fatigable weakness and include autoimmune, toxic, and genetic conditions. Adults with NMJ disorders are most often antibody mediated, with MG being the most common, having a prevalence of approximately 1 in 10,000, and with women being affected about twice as often as men.
View Article and Find Full Text PDF